Enable Injections closed a $30 million Series A round, which will go toward commercializing its adhesive drug-delivering patch aimed at reducing pain and error when self-delivering drugs.
The Enable Injector adheres to the body and delivers subcutaneous doses of biologics, such as insulin, comfortably. The patient pushes a button and the device inserts a needle, delivers the drug and, upon removal, retracts the needle. The flow of the drug being delivered adapts to each individual user, and the device has a pause function, allowing the patient to take a break at any time, the company said. It is available in a range of volumes from 5 mL to 50 mL.
Most biologics must be delivered in doses greater than 5 mL, but the typical syringe dose is 1 mL, the company said in a statement. And while delivering biologics subcutaneously is preferred, current tech doesn’t allow that, the company said.
“The Enable injector has the potential to transform the delivery of a significant and growing category of drugs,” said Bob Coy, CEO of CincyTech, which participated in financing, in the statement. “It offers comfort and convenience to patients, a point of differentiation to pharmaceutical companies, and a reduction of costs to the health care system."
ORI Healthcare Fund led the financing, with participation from CincyTech, Cincinnati Children’s Hospital, CintriFuse and the Ohio Innovation Fund. Enable Injections is also developing vial and syringe transfer systems to move a drug into its Enable Injector.